Last reviewed · How we verify
LUM015
At a glance
| Generic name | LUM015 |
|---|---|
| Sponsor | Lumicell, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers (PHASE1, PHASE2)
- Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies (PHASE1, PHASE2)
- Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients (PHASE2)
- Feasibility of the LUM Imaging System for Detection of Cancer to the Brain (NA)
- Feasibility Study of LUM Imaging System for Pancreatic Cancer (NA)
- Investigation of Novel Surgical Imaging for Tumor Excision (PHASE3)
- Intraoperative Detection of Residual Cancer in Breast Cancer (PHASE2)
- Feasibility Study of Intraoperative Imaging in Breast Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LUM015 CI brief — competitive landscape report
- LUM015 updates RSS · CI watch RSS
- Lumicell, Inc. portfolio CI